Replies to post #3810 on Mast Therapeutics, Inc. (MSTX)

[Live42Day]

I am not selling until multi-dollars. Once approved, ANX'es 2 drugs will be competing against the big boys in a $3B+ cancer drug market. Since ANX'es drugs are a reformulation of already approved drugs (with less side effects), I expect that they will be approved with no problems.

ANX reminds me so much of HGSI (ran from the pennies to $30+). Both have smiliar share structures and frankly I think that ANX should have a higher MC, based on revenue potential from their drugs and lower risk since their drugs are a reformulation of already approved cancer drugs.

ANX should already be trading for $5+. Once more investors realize the potential (big institutional buyers), ANX goes MUCH higher IMO.

http://seekingalpha.com/instablog/503983-tmackie/42955-adventrx-pharmaceuticals-anx-submits-cancer-drug-to-nda-amid-takeover-rumors